<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rapport Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Rapport Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rapport-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b55378dffbe2df113905.webp</url>
<title>Rapport Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-to-present-new-phase-2-treatment-follow-up-data-for-rap-219-in-focal-onset-seizures-at-the-2026-american-academy-of-neurology-annual-meeting-2</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-to-present-new-phase-2-treatment-follow-up-data-for-rap-219-in-focal-onset-seizures-at-the-2026-american-academy-of-neurology-annual-meeting-2</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3</description>
</item>
<item>
<title>Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-and-tenacia-biotechnology-announce-strategic-collaboration-for-the-development-and-commercialization-of-rap-219-in-greater-china</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-and-tenacia-biotechnology-announce-strategic-collaboration-for-the-development-and-commercialization-of-rap-219-in-greater-china</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of</description>
</item>
<item>
<title>Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announces-accelerated-initiation-rap-219-phase-3-program</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announces-accelerated-initiation-rap-219-phase-3-program</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of</description>
</item>
<item>
<title>Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology</description>
</item>
<item>
<title>Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announces-new-data-and-post-hoc-analysis-demonstrating-magnitude</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announces-new-data-and-post-hoc-analysis-demonstrating-magnitude</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with</description>
</item>
<item>
<title>Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-new-phase-2a-data-analysis-further-characterizing-rap</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-new-phase-2a-data-analysis-further-characterizing-rap</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across</description>
</item>
<item>
<title>Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-third-quarter-2025-financials-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-third-quarter-2025-financials-and-provides-business</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania</description>
</item>
<item>
<title>Rapport Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-upcoming-investor-conferences-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-upcoming-investor-conferences-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology</description>
</item>
<item>
<title>Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-td-cowens-5th-annual-novel-mechanisms</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-td-cowens-5th-annual-novel-mechanisms</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Rapport Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-pricing-public-offering-common-stock-2025-09-10</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-pricing-public-offering-common-stock-2025-09-10</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Rapport Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-proposed-public-offering-common-stock-2025-09-08</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-proposed-public-offering-common-stock-2025-09-08</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-positive-topline-results-phase-2a-clinical-trial-rap-219-patients</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-announces-positive-topline-results-phase-2a-clinical-trial-rap-219-patients</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in</description>
</item>
<item>
<title>Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announce-topline-results-rap-219-phase-2a-trial-focal-onset</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-announce-topline-results-rap-219-phase-2a-trial-focal-onset</guid>
<pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-second-quarter-2025-financials-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-second-quarter-2025-financials-and-provides-business</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial</description>
</item>
<item>
<title>Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-hosts-investor-and-analyst-day-provides-corporate-updates-2025</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-hosts-investor-and-analyst-day-provides-corporate-updates-2025</guid>
<pubDate>Mon, 02 Jun 2025 04:00:00 GMT</pubDate>
<description>Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 BOSTON and SAN DIEGO, June 02, 2025</description>
</item>
<item>
<title>Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-jefferies-global-healthcare-conference-and-goldman</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-participate-jefferies-global-healthcare-conference-and-goldman</guid>
<pubDate>Tue, 27 May 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the</description>
</item>
<item>
<title>Rapport Therapeutics to Host 2025 Investor and Analyst Day</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-host-2025-investor-and-analyst-day-2025-05-21</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-host-2025-investor-and-analyst-day-2025-05-21</guid>
<pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the</description>
</item>
<item>
<title>Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-first-quarter-2025-financials-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-reports-first-quarter-2025-financials-and-provides-business</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025RAP-219 Phase 2a</description>
</item>
<item>
<title>Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-data-2025-american-academy-neurology-annual-meeting-2025</link>
<guid isPermaLink="true">https://6ix.com/company/rapport-therapeutics-inc-common-stock/news/rapport-therapeutics-present-data-2025-american-academy-neurology-annual-meeting-2025</guid>
<pubDate>Fri, 21 Mar 2025 04:00:00 GMT</pubDate>
<description>BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage</description>
</item>
</channel>
</rss>